Drug Name Synthroid

Generic versions are available in Canada and were FDA approved in September 2006. Mylan Pharmaceuticals was recently granted final approval for generic topiramate 25, 100, and 200 mg tablets and sprinkle capsules by the FDA for sale in the US. 50 mg tablets were granted tentative approval. The last patent for topiramate in the U.S. was for pediatric use; this patent expired on February 28, 2009.
Flomax, Alna, Josir, Pradif, Secotex, Urolosin, Mecir (tamsulosin). Indicated for the treatment of Lower urinary tract Symptoms (LUTS) associated with benign prostate hyperplasia and available since 1996 as capsule controlled release formulation in the main world markets. Starting in 2005, a new tablet formulation based on the OCAS (Oral Controlled Absorption System) technology has been made available in many European markets and in Canada.

Rimonabant (also known as SR141716; trade names Acomplia, Bethin, Monaslim, Remonabent, Riobant, Slimona, Rimoslim, Zimulti, and Riomont) is an anorectic antiobesity drug. It is an inverse agonist for the cannabinoid receptor CB1. Its main effect is reduction in appetite. Rimonabant was the first selective CB1 receptor blocker to be approved for use anywhere in the world.
Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites. Anaerobic bacteria are single-celled, living organisms that thrive in environments in which there is little oxygen (anaerobic environments) and can cause disease in the abdomen (bacterial peritonitis), liver (liver abscess), and pelvis (abscess of the ovaries and the Fallopian tubes).